{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Patients with resected colon carcinoma","Colon Cancer","Colorectal Neoplasms","Neoplasms","Colonic Neoplasms"],"disease":["Colon Cancer","Colorectal Neoplasms","Colonic Neoplasms","Neoplasms","Patients With Resected Colon Carcinoma"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2268259"],"location":["Belgium"],"study_start_month":["2"],"keyword":["Neoplasms by Site","Aspirin","Gastrointestinal Neoplasms","Intestinal Diseases","Digestive System Diseases","Intestinal Neoplasms","Colonic Diseases","Digestive System Neoplasms","Disease Attributes","Pathologic Processes"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"ASPIRIN Trial Belgium","description":"The purpose of this study is to determine whether acetylsalicylic acid is effective on the recurrence and survival of colon cancer patients.","dates":{"creation":"2018-02-15"},"accession":"2268259","cross_references":{"ClinicalTrials___gov":["NCT03464305"],"EU Clinical Trials Register":["2017-001397-41"]}}